NVS - Novartis' Investigational Therapy Shows Promising Action In Rare Kidney Disease | Benzinga
Novartis AG (NYSE: NVS) announced topline results from the pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study at nine months of iptacopan, an investigational factor B inhibitor targeting the alternative complement pathway.
The study demonstrated superiority over placebo in reducing proteinuria (protein in urine). It provided a clinically meaningful and statistically significant proteinuria reduction on top of supportive care in patients with IgA nephropathy (IgAN), a complement-mediated disease.
In the study, the ...